Efficient Drug Discovery Through Collaboration with External Partners, Universities and Public Institutions
First written in FY2024. 7 of 8 entries say "Advanced", first in FY2025. Latest entry: 2026-10-15.
25 other companies' latest entry also says "Advanced".
- FY2025AdvancedAnnual report
「In July 2025, the Company began joint research with 株式会社デ・ウエスタン・セラピテクス研究所, and in August 2025 with 千寿製薬株式会社, to explore the potential of different Company compounds as treatments for ophthalmic diseases.」
In addition to its existing collaborations with universities, public institutions and pharmaceutical companies, the Company began joint research in July and August 2025 with companies to explore applications in ophthalmic diseases. - FY2024First statedAnnual report
「The Company conducts its business by concentrating on management and research activities, including exploratory, preclinical and clinical research, particularly the discovery, evaluation and optimization of candidate compounds and clinical trials, while outsourcing to external partners work in which they specialize, especially basic research, the manufacture of active pharmaceutical ingredients and drug products, and distribution and sales.」
The Company has explicitly adopted an operating model in which it focuses on management and the discovery, evaluation and optimization of candidate compounds and clinical trials, while outsourcing basic research, manufacturing, distribution and sales.